Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Deciphera Pharmaceuticals LLC

Healthcare US DCPH

NoneUSD
0.00(0%)

Last update at 2024-06-20T21:00:39.447206Z

Day Range

--
LowHigh

52 Week Range

9.9025.55
LowHigh

Fundamentals

  • Previous Close 25.59
  • Market Cap2206.00M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-204.60600M
  • Revenue TTM174.91M
  • Revenue Per Share TTM2.03
  • Gross Profit TTM -62.55500M
  • Diluted EPS TTM-2.21

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -178.20900M -299.96400M -266.48900M -192.25600M -99.85400M
Minority interest - - - - -
Net income -178.93100M -296.83700M -266.48900M -191.49300M -99.85400M
Selling general administrative 120.17M 136.25M 114.08M 68.12M 21.21M
Selling and marketing expenses - - - - -
Gross profit 125.27M 93.22M 41.86M 25.00M 0.00000M
Reconciled depreciation 2.95M 3.01M 2.31M 0.83M 0.32M
Ebit -185.66800M -303.09100M -271.19000M -200.72600M -100.08700M
Ebitda -182.72200M -300.07700M -264.18400M -192.18900M -99.77000M
Depreciation and amortization 2.95M 3.01M 7.01M 8.54M 0.32M
Non operating income net other 4.51M 0.11M 4.70M 8.54M 4.33M
Operating income -182.72200M -300.07700M -271.19000M -200.72600M -104.09900M
Other operating expenses 316.76M 396.23M 313.28M 225.73M 104.10M
Interest expense 4.51M 0.11M 4.70M 0.07M 0.08M
Tax provision 0.72M - - - -
Interest income 4.51M 0.11M 4.70M 8.54M 4.33M
Net interest income 4.51M 0.11M 4.70M 8.47M 4.25M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.72M -3.12700M -4.70100M -0.76300M 4.33M
Total revenue 134.04M 96.15M 42.09M 25.00M 0.00000M
Total operating expenses 307.99M 393.29M 313.05M 225.73M 104.10M
Cost of revenue 8.77M 2.93M 0.23M - 0.00000M
Total other income expense net 4.51M 0.11M 4.70M 8.47M 4.25M
Discontinued operations - - - - -
Net income from continuing ops -178.93100M -299.96400M -266.48900M -192.25600M -99.85400M
Net income applicable to common shares -178.93100M -299.96400M -266.48900M -192.25600M -99.85400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 473.57M 454.04M 429.48M 642.43M 622.41M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 21.72M 25.48M 18.66M 12.49M 13.83M
Total liab 122.65M 112.35M 124.76M 98.76M 75.94M
Total stockholder equity 350.92M 341.69M 304.72M 543.68M 546.47M
Deferred long term liab - - - - -
Other current liab 1.95M 64.62M 1.07M 55.23M 38.72M
Common stock 0.81M 0.68M 0.58M 0.58M 0.52M
Capital stock 0.81M 0.68M 0.58M 0.58M 0.52M
Retained earnings -1428.30500M -1233.36300M -1054.43200M -754.46800M -487.97900M
Other liab - - - - -
Good will - - - - -
Other assets - 3.28M 3.11M 3.10M 1.51M
Cash 83.51M 64.74M 87.06M 135.90M 120.32M
Cash and equivalents - - - - -
Total current liabilities 100.28M 86.47M 96.77M 69.99M 60.04M
Current deferred revenue 68.35M - 79.70M - -
Net debt -57.62800M -35.62700M -56.20200M -104.67600M -102.66900M
Short term debt 3.50M 3.23M 2.87M 2.46M 1.75M
Short long term debt - - - - -
Short long term debt total 25.88M 29.11M 30.86M 31.22M 17.65M
Other stockholder equity 1777.84M 1575.36M 1358.52M 1297.56M 1033.82M
Property plant equipment - 6.71M 8.61M 9.58M 27.49M
Total current assets 381.10M 392.96M 339.01M 584.03M 593.41M
Long term investments 46.70M 14.55M 41.95M 9.38M 1.51M
Net tangible assets - 341.69M 304.72M 543.68M 546.47M
Short term investments 222.71M 259.75M 198.57M 416.03M 459.26M
Net receivables 31.95M 22.43M 20.59M 13.90M -
Long term debt - - - - -
Inventory 21.21M 20.56M 14.12M 5.72M -
Accounts payable 26.48M 18.61M 13.13M 12.31M 19.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.58M -0.98300M 0.05M 0.01M 0.11M
Additional paid in capital - - - - -
Common stock total equity - 0.68M 0.58M 0.58M 0.52M
Preferred stock total equity - - - - -
Retained earnings total equity - -1233.36300M -1054.43200M -754.46800M -487.97900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 8.28M 3.28M 3.11M 3.10M 1.51M
Deferred long term asset charges - - - - -
Non current assets total 92.47M 61.08M 90.47M 58.40M 29.00M
Capital lease obligations 25.88M 29.11M 30.86M 31.22M 17.65M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -33.46800M 182.82M 33.77M -455.58700M -1.06900M
Change to liabilities -10.14300M 28.12M 6.39M 35.40M 8.84M
Total cashflows from investing activities -34.30900M 176.85M 28.46M -460.52200M -2.19400M
Net borrowings - - - -1.29400M -0.18700M
Total cash from financing activities 164.99M 14.89M 226.80M 436.37M 185.99M
Change to operating activities -28.79600M 16.84M 10.82M 14.86M -0.92500M
Net income -178.93100M -299.96400M -266.48900M -192.25600M -99.85400M
Change in cash -22.32200M -48.83400M 15.58M -173.44400M 97.01M
Begin period cash flow 87.06M 135.90M 120.32M 293.76M 196.75M
End period cash flow 64.74M 87.06M 135.90M 120.32M 293.76M
Total cash from operating activities -152.86200M -240.82400M -239.68300M -149.29600M -86.78300M
Issuance of capital stock 163.78M 8.59M 207.23M 432.40M 185.93M
Depreciation 2.95M 3.01M 2.31M 0.83M 0.32M
Other cashflows from investing activities - -4.00000M 0.00700M -0.44100M -1.06900M
Dividends paid - - - - -
Change to inventory -7.10900M -10.15500M -3.24100M -3.24100M -3.24100M
Change to account receivables -1.78400M -6.69900M -13.89600M -13.89600M -13.89600M
Sale purchase of stock 164.99M 14.89M 226.80M 437.67M 186.17M
Other cashflows from financing activities 1.22M 6.30M 19.57M 5.27M 0.24M
Change to netincome 51.94M 46.08M 37.13M 20.41M 9.69M
Capital expenditures 0.84M 5.97M 5.32M 4.93M 1.12M
Change receivables -1.78400M -6.69900M -13.89600M - -
Cash flows other operating -8.48600M -2.99800M -0.27100M -9.68200M -5.77000M
Exchange rate changes - 0.25M - - -
Cash and cash equivalents changes -22.17700M -48.83400M 15.58M -173.44400M 97.01M
Change in working capital -31.64800M 0.82M -13.85200M 25.72M 3.07M
Stock based compensation 51.94M 46.08M 37.14M 20.41M 9.69M
Other non cash items 2.83M 7.45M 2.83M -3.99900M -90.86100M
Free cash flow -153.70300M -246.79400M -244.99900M -154.23100M -87.90800M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DCPH
Deciphera Pharmaceuticals LLC		 - -% - - - 12.61 6.98 11.20 -4.5343
ZTS
Zoetis Inc		 0.95 1.25% 76.84 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.42 1.37% 30.98 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 149.28 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 0.48 1.12% 43.42 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Deciphera Pharmaceuticals LLC

200 Smith Street, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Mr. Steven L. Hoerter Pres, CEO & Director 1971
Dr. Daniel L. Flynn Ph.D. Exec. VP, Chief Scientific Officer & Founder 1955
Mr. Thomas Patrick Kelly J.D. Exec. VP, CFO & Treasurer 1971
Mr. Daniel C. Martin Sr. VP & Chief Commercial Officer 1975
Dr. Matthew L. Sherman M.D. Exec. VP & Chief Medical Officer 1956
Dr. Stephen B. Ruddy Ph.D. Sr. VP & Chief Technical Officer 1964
Jennifer Larson Sr. VP of Fin. & Investor Relations NA
Mr. Jeffrey M. Held J.D. Sr. VP & Gen. Counsel NA
Ms. Lisa Amaya Price Sr. VP & Chief HR Officer NA
Ms. Jama Pitman Sr. VP of Regulatory, Quality & Portfolio Management 1979

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions